Traders should note the stock has already converged to near the $25.00 deal price (closed at $25.00 on June 8, 2026), indicating minimal arbitrage spread. The primary risk is deal completion, focus on regulatory approvals from the Required Government Authorities (Belgium, Sweden, Australia, Saudi Arabia, Mexico, Canada) and the HSR waiting period. If the stock trades below $25.00, the spread reflects execution risk rather than valuation uncertainty. Monitor for any competing Superior Proposal triggering the 4-business-day go-shop match period.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Jun 11 $24.98entry
- T+1 · 5mo ago −0.08%α −0.62% · $24.96
- T+5 · 5mo ago −0.44%α −0.87% · $24.87
- T+20 · 4mo ago −0.16%α −2.05% · $24.94
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Avanos Medical enters a definitive agreement to be acquired by American Industrial Partners (AIP) for $25.00 per share in cash, representing a 72% premium to the last unaffected closing price of $14.53. The all-cash deal values Avanos at approximately $1.17 billion in equity value, with total required funds of ~$1.42 billion including debt repayment and equity award settlements. The board unanimously recommends approval; a special stockholder vote is set for July 22, 2026.
Key Financial Metrics
Key Facts
- Merger consideration: $25.00 per share in cash, no stock component or CVR
- Premium of ~72% based on $14.53 closing price on April 13, 2026 (last pre-announcement trading day)
- Equity commitment of $1.4 billion from AIP Fund; no financing condition for Parent
- Total required funds for the deal: ~$1.42 billion including debt repayment and equity award settlements
- Board of Directors unanimous recommendation FOR the merger proposal
- Special meeting scheduled for July 22, 2026; record date June 18, 2026
- J.P. Morgan issued fairness opinion that $25.00 per share is fair from a financial point of view
- Approval requires majority of outstanding shares; abstentions and failures to vote count as AGAINST
- Appraisal rights available under DGCL Section 262 for dissenting stockholders
- Termination fee payable by Avanos: $37.5 million in certain circumstances
- Closing expected in second half of 2026, subject to regulatory approvals (HSR, multiple foreign jurisdictions) and stockholder vote
- Directors and executive officers holding ~0.35% of outstanding shares expected to vote in favor
Financial Impact
$25.00 per share in cash, ~72% premium to unaffected price of $14.53, total equity value ~$1.17B based on 46.85M shares outstanding
Risk Factors
- Regulatory delays or failure to obtain Required Regulatory Approvals (multiple foreign jurisdictions)
- Antitrust challenge in any of the six Required Government Authority countries
- Stockholder vote failure: abstentions and non-votes count as AGAINST, requiring majority of all outstanding shares
- Material Adverse Effect clause could allow termination if Avanos business deteriorates significantly
- Litigation risk: though none filed as of proxy date, deal-related lawsuits are common
- Termination fee of $37.5M is not large relative to deal value (~3.2%) but could deter competing bidders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFM14A Filing (Primary) | 0001104659-26-072432 |
| Document: tm2614353-2_defm14a.htm | 0001104659-26-072432 |
Track record
7 reports on AVNS
The track record builds as more bullish or bearish reports settle.
Filters
- Jul 27, 202616w ago 25-NSE Neutral 5/10 Entry $24.99 No price data
- Jul 2, 202619w ago 8-K / DEFA14A Bullish 7/10 Entry $24.93 to $24.94 ▲ +0.04% −0.89% vs SPY
- Jun 10, 202622w ago DEFM14A Bullish 8/10 Viewing Entry $24.98 to $24.87 ▼ −0.44% −0.87% vs SPY
- May 5, 202627w ago DEFA14A Neutral 5/10 Entry $24.72 to $24.73 ▲ +0.04% −1.09% vs SPY
- Apr 23, 202629w ago DEFA14A Bullish 8/10 Entry $24.71 to $24.65 ▼ −0.24% −1.72% vs SPY
- Apr 14, 202630w ago DEFA14A Neutral 4/10 Entry $24.63 to $24.64 ▲ +0.04% −1.35% vs SPY
- Feb 26, 202637w ago 8-K Neutral 5/10 Entry $14.49 to $13.79 ▼ −4.83% −3.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers